DK0886527T3 - Farmaceutiske sammensætninger indeholdende naturligt humant alfa-interferon - Google Patents

Farmaceutiske sammensætninger indeholdende naturligt humant alfa-interferon

Info

Publication number
DK0886527T3
DK0886527T3 DK97905395T DK97905395T DK0886527T3 DK 0886527 T3 DK0886527 T3 DK 0886527T3 DK 97905395 T DK97905395 T DK 97905395T DK 97905395 T DK97905395 T DK 97905395T DK 0886527 T3 DK0886527 T3 DK 0886527T3
Authority
DK
Denmark
Prior art keywords
natural human
human alpha
pharmaceutical compositions
compositions containing
containing natural
Prior art date
Application number
DK97905395T
Other languages
Danish (da)
English (en)
Inventor
Giulio Tarro
Renzo Brozzo
Original Assignee
Unihart Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from IT96RM000136 external-priority patent/IT1283945B1/it
Priority claimed from ITRM960427 external-priority patent/IT1284852B1/it
Application filed by Unihart Corp filed Critical Unihart Corp
Application granted granted Critical
Publication of DK0886527T3 publication Critical patent/DK0886527T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/212—IFN-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Virology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
DK97905395T 1996-02-28 1997-02-27 Farmaceutiske sammensætninger indeholdende naturligt humant alfa-interferon DK0886527T3 (da)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
IT96RM000136 IT1283945B1 (it) 1996-02-28 1996-02-28 Uso dell'interferone alfa naturale umano da cellule linfoblastoidi per la terapia delle epatiti virali, neoplasie e sindromi da
ITRM960427 IT1284852B1 (it) 1996-06-14 1996-06-14 Uso dell'interferone alfa naturale umano da cellule leucocitarie per la terapia delle epatiti virali, neoplasie e sindromi da
PCT/IT1997/000040 WO1997031649A1 (en) 1996-02-28 1997-02-27 PHARMACEUTICAL COMPOSITIONS COMPRISING NATURAL HUMAN α-INTERFERON

Publications (1)

Publication Number Publication Date
DK0886527T3 true DK0886527T3 (da) 2002-03-04

Family

ID=26332096

Family Applications (1)

Application Number Title Priority Date Filing Date
DK97905395T DK0886527T3 (da) 1996-02-28 1997-02-27 Farmaceutiske sammensætninger indeholdende naturligt humant alfa-interferon

Country Status (14)

Country Link
US (1) US6884411B1 (ko)
EP (1) EP0886527B1 (ko)
JP (1) JP2000506839A (ko)
KR (1) KR100394382B1 (ko)
AT (1) ATE205397T1 (ko)
AU (1) AU722987B2 (ko)
BR (1) BR9707772A (ko)
DE (1) DE69706657T2 (ko)
DK (1) DK0886527T3 (ko)
EA (1) EA001147B1 (ko)
ES (1) ES2160927T3 (ko)
GE (1) GEP20012489B (ko)
PT (1) PT886527E (ko)
WO (1) WO1997031649A1 (ko)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE60332358D1 (de) * 2002-09-09 2010-06-10 Hanall Pharmaceutical Co Ltd Protease-resistente modifizierte interferon alpha polypeptide
ITMI20030826A1 (it) * 2003-04-18 2004-10-19 Unihart Corp Composizione farmaceutica contenente interferone per il
WO2006032711A1 (es) * 2004-08-18 2006-03-30 Instituto Científico Y Tecnológico De Navarra S.A. Uso del factor de crecimiento semejante a la insulina tipo i y de interferón alfa en el tratamiento de una enfermedad hepática crónica, kit y composiciones que los comprenden
ES2303492A1 (es) * 2004-08-18 2008-08-01 Instituto Cientifico Y Tecnologico De Navarra S.A. Uso del factor de crecimiento semejante a la insulina tipo i y de interferon alfa en el tratamiento de una enfermedad hepatica cronica, kit y composiciones que los comprenden.
US20080260820A1 (en) * 2007-04-19 2008-10-23 Gilles Borrelly Oral dosage formulations of protease-resistant polypeptides

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA878295B (en) 1986-11-06 1988-05-03 Amarillo Cell Culture Co. Inc. Treatment of immuno-resistant disease
CA1320905C (en) * 1986-11-06 1993-08-03 Joseph M. Cummins Treatment of immuno-resistant disease
TW224053B (ko) * 1991-09-13 1994-05-21 Paul B Chretien
US6387365B1 (en) * 1995-05-19 2002-05-14 Schering Corporation Combination therapy for chronic hepatitis C infection
US5980884A (en) * 1996-02-05 1999-11-09 Amgen, Inc. Methods for retreatment of patients afflicted with Hepatitis C using consensus interferon
HUP9602024A3 (en) * 1996-07-25 1999-05-28 Toth Sandor Pharmaceutical composition containing aminoacid for external use

Also Published As

Publication number Publication date
KR19990082559A (ko) 1999-11-25
KR100394382B1 (ko) 2004-02-05
AU2229997A (en) 1997-09-16
BR9707772A (pt) 2000-01-04
PT886527E (pt) 2001-12-28
EA199800770A1 (ru) 1999-02-25
EP0886527B1 (en) 2001-09-12
US6884411B1 (en) 2005-04-26
DE69706657D1 (de) 2001-10-18
EA001147B1 (ru) 2000-10-30
GEP20012489B (en) 2001-07-25
JP2000506839A (ja) 2000-06-06
DE69706657T2 (de) 2002-06-20
EP0886527A1 (en) 1998-12-30
ES2160927T3 (es) 2001-11-16
AU722987B2 (en) 2000-08-17
WO1997031649A1 (en) 1997-09-04
ATE205397T1 (de) 2001-09-15

Similar Documents

Publication Publication Date Title
AR012614A1 (es) Una composicion farmaceutica para la fabricacion de un medicamento destinado para el tratamiento de una infeccion viral susceptible de tratamientocon interferon alfa, un metodo para la fabricacion de un medicamento, el uso de peg12000-ifn alfa para la fabricacion de un medicamento
DK0911033T4 (da) Anvendelse af konsensusinterferon til reduktion af bivirkningerne af interferonbehandling i viral hepatitis
HUP0103423A2 (hu) Ribavirint és alfa-interferont tartalmazó kombinált terápia vírusellenes kezelésben nem részesült, krónikus hepatitis C fertőzött paciensek kezelésében
DK0871748T3 (da) Indgivelse af biologisk aktive polypeptider
ATE165000T1 (de) Dosierungsform zur verzoegerten wirkstofffreisetzung
HUP0101293A2 (hu) AspB28-humán inzulint tartalmazó inhalációs gyógyászati készítmény és alkalmazása
ITRM910922A1 (it) Composizione farmaceutica anticefalalgica per somministrazione endonasale, procedimento per prepararla e suo impiego terapeutico
HUP0100092A2 (hu) Kombinációs terápia kimutatható HCV-RNS eradikációjára krónikus hepatitis-C fertőzött betegekben
MX171191B (es) Composiciones farmaceuticas de glipizida
GEP19981482B (en) Use of 1,3 - Oxatiolan Nucleozides Analoges for Treatment of Hepatitis B
DK486588A (da) Konjungater af cytokininer med immunglobuliner
DK0527835T3 (da) Doseringsform til afgivelse af et anti-Parkinsonmiddel
HUP0102033A2 (hu) PEG IFN-alfa és ribavirin felhasználása krónikus hepatitis C kezelésére
RU92016463A (ru) Применение производных цистина для изготовления лекарственных препаратов с иммуномоделирующим действием, фармацевтические композиции на их основе
HK1030157A1 (en) Use of consensus interferon and compositions comprising consensus interferon.
DK0886527T3 (da) Farmaceutiske sammensætninger indeholdende naturligt humant alfa-interferon
BR0108997A (pt) Terapia imune adjuvante para hiv
HK1041215A1 (en) Use of thymosin alpha 1 in combination with lamivudine or in combination with lamivudine and famciclovir in manufacturing pharmaceutical combination preparations for treating hepatitis b infection.
ES2089286T3 (es) Nuevas 2-amino-5-ciano-1,4-dihidropiridinas, procedimiento para su preparacion y su uso en medicamentos.
AU2880595A (en) Use of pharmaceutical agents for restoring, alleviation, or treatment of immunodeficiency, including the alleviation or treatment of the immune dysfunction related to infection with human immunodeficiency viruses (hiv) or related viruses
KR950702838A (ko) 인터루킨-4(IL-4)를 사용한 사람 면역결핍 바이러스(HIV) 복제의 억제방법(Method for inhibiting HIV replication using IL-4)
OA08768A (fr) Traitement du virus su SIDA par l'interféron alpha humain recombinant.
HUP9902188A2 (hu) Természetes humán alfa-interferont tartalmazó gyógyszerkészítmények
IT1284852B1 (it) Uso dell'interferone alfa naturale umano da cellule leucocitarie per la terapia delle epatiti virali, neoplasie e sindromi da
IT1283945B1 (it) Uso dell'interferone alfa naturale umano da cellule linfoblastoidi per la terapia delle epatiti virali, neoplasie e sindromi da